Investment trust RTW Biotech Opportunities (RTW) has marked its second success this month with the takeover of Penumbra. The company is being acquired by Boston Scientific (BSX) at a 19% premium in one of the first deals of 2026. At the end of last week, portfolio company Aktis Oncology (AKTS) completed its IPO on New … Continue reading RTW Biotech marks second success of 2026